Precigen Inc (PGEN)

The past six months have been transformational for Precigen's stock, largely driven by the commercialization of PAPZIMEOS. The FDA approved PAPZIMEOS in August 2025, marking Precigen's transition into a commercial-stage biopharmaceutical company. In November 2025, PAPZIMEOS commenced US commercial sales, generating $3.4 million in net product revenue for Q4 2025. In March 2026, Precigen reported its full-year 2025 financial results and provided business updates, with revenue surging to $9.7 million, a 149% increase from 2024, and projected Q1 2026 revenue to exceed $18 million for PAPZIMEOS. A permanent J-code (J3404) for PAPZIMEOS became effective on April 1, 2026, which is expected to streamline the claims process and facilitate broader patient access. Analyst price targets have been raised by firms like H.C. Wainwright and Citizens, citing the strong commercial trajectory of PAPZIMEOS. The share price as of April 10, 2026, was $4.16, representing a significant increase of 197.14% from April 11, 2025, when it was $1.40 per share.

There is no explicit information indicating demand seasonality for Precigen, Inc.'s products and services.

Precigen, Inc. is a biotechnology company focused on developing precision medicines, including gene and cell therapies and immunotherapies. The company specializes in advancing scientific breakthroughs from early proof-of-concept through to commercialization, leveraging its proprietary technology platforms. Its core therapeutic areas include immuno-oncology, autoimmune disorders, and infectious diseases. Major products and platforms include PAPZIMEOS, an immunotherapy for adults with recurrent respiratory papillomatosis (RRP), AdenoVerse Platform, UltraCAR-T Platform, and UltraPorator.

Precigen, Inc. is headquartered in Germantown, Maryland, United States. The commercial launch of PAPZIMEOS is primarily focused on the United States, with a commercial footprint designed to cover approximately 90% of the patient potential across about 500 hospital systems. The company is also actively pursuing geographic expansion, with a Marketing Authorization Application for PAPZIMEOS currently under review by the European Medicines Agency (EMA).

Precigen's brand reputation in the past year has been significantly bolstered by the FDA approval and successful commercial launch of PAPZIMEOS. This approval has been a major positive, transitioning the company to a commercial-stage entity. PAPZIMEOS is being recognized as the new standard of care for adult RRP, supported by strong physician and patient demand, and broad payer coverage in the US. An expert consensus paper also recommended PAPZIMEOS as the new standard of care first-line treatment for adults with RRP in the US.

Precigen, Inc. has a significant number of institutional owners and shareholders. As of April 9, 2026, there were 190 institutional owners holding a total of 137,134,722 shares. Major institutional shareholders include Patient Capital Management, LLC, BlackRock, Inc., Point72 Asset Management, L.P., State Street Corp, Vanguard Group Inc, Tang Capital Management Llc, Fmr Llc, and Geode Capital Management, Llc. Third Security, LLC is noted as a top institutional holder, owning 29.40% of the holding with 104,038,349 shares as of March 29, 2026. E. Merck KG also holds a notable stake. Randal J. Kirk is the largest individual Precigen shareholder, owning 258,555,888 shares, representing 73.05% of the company.